|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravitreal injection
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
S01LA04
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:brand
|
gptkb:Lucentis
|
|
gptkbp:CASNumber
|
gptkb:347396-82-1
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:form
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ranibizumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Novartis
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
VEGF-A inhibitor
|
|
gptkbp:molecularWeight
|
48 kDa
|
|
gptkbp:monitors
|
ophthalmologist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
ophthalmology
|
|
gptkbp:PubChem_CID
|
gptkb:DB01270
none
|
|
gptkbp:routeOfAdministration
|
intravitreal
|
|
gptkbp:sideEffect
|
conjunctival hemorrhage
eye pain
increased intraocular pressure
intraocular inflammation
|
|
gptkbp:target
|
gptkb:vascular_endothelial_growth_factor_A
|
|
gptkbp:UNII
|
N6J8409Y7I
|
|
gptkbp:usedFor
|
gptkb:diabetic_macular_edema
age-related macular degeneration
macular edema following retinal vein occlusion
myopic choroidal neovascularization
|
|
gptkbp:bfsParent
|
gptkb:F-BVFA
gptkb:Lucentis
|
|
gptkbp:bfsLayer
|
5
|